Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae -induced mouse model of chronic asthma

• Ikeda Masaki

  Department of Respiratory Medicine, Kawasaki Medical School

• Katoh Shigeki

  Department of Respiratory Medicine, Kawasaki Medical School

• Shimizu Hiroki

  Department of Respiratory Medicine, Kawasaki Medical School

• Hasegawa Akira

  Research Laboratories, Torii Pharmaceutical Co., Ltd.

• Ohashi-Doi Katsuyo

  Research Laboratories, Torii Pharmaceutical Co., Ltd.

• Oka Mikio

  Department of Respiratory Medicine, Kawasaki Medical School

書誌事項

タイトル別名

• Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a <i>Dermatophagoides farinae</i>-induced mouse model of chronic asthma

抄録

Background: Allergen-specific sublingual immunotherapy is a potential disease-modifying treatment for allergic asthma. Galectin-9 (Gal-9), a β-galactoside-binding protein with various biologic effects, acts as an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and enhancing transforming growth factor (TGF)-β signaling. We investigated the efficacy of sublingually administered Gal-9 as an adjuvant to a specific allergen in a Dermatophagoides farinae (Df)-induced mouse model of chronic asthma. Methods: BALB/c mice were intranasally sensitized with Df extract 5 days/week for 5 weeks, and then sublingual Df-allergen extract for 2 weeks (5 days/week). Three days after the final sublingual treatment, mice were intranasally challenged with Df extract. The early asthmatic response (EAR) was evaluated 5 min after the last Df challenge. Airway hyperresponsiveness (AHR) was assayed and bronchoalveolar lavage (BAL) was performed 24 h after the last allergen challenge. Serum IgE and cytokine levels, and number of inflammatory cells in the BAL fluid (BALF) were analyzed. Results: Sublingual Df treatment in the presence of Gal-9, but not alone, significantly reduced AHR; EAR; number of eosinophils and interleukin-13 in the BALF; and serum IgE levels. BALF TGF-β1 levels were significantly increased in the presence of Gal-9 compared with Df alone. Treg depletion blocked the inhibitory effects of Gal-9 on the EAR, AHR, eosinophilic airway inflammation, and Df-specific serum IgE levels, and suppressed BALF TGF-β1 levels. Conclusions: Gal-9 exhibited beneficial effects of sublingual Df allergen-specific immunotherapy in a Df-induced mouse model of chronic asthma, possibly by Gal-9-induced TGF-β1 production in the lung.

収録刊行物

• Allergology International

  Allergology International 66 (3), 432-439, 2017

  一般社団法人日本アレルギー学会

キーワード

• Galectin-9
• Mite allergen
• Mouse
• SLIT
• TGF-β1

詳細情報

• CRID: 1390282679609481728
• NII論文ID: 130005858794
• DOI: 10.1016/j.alit.2016.10.007
• ISSN: 14401592
• ISSN: 13238930
• Web Site: https://api.elsevier.com/content/article/PII:S1323893016301617?httpAccept=text/xml
• Web Site: https://api.elsevier.com/content/article/PII:S1323893016301617?httpAccept=text/plain
• Web Site: https://search.jamas.or.jp/link/ui/2018093004
• 本文言語コード: en
• データソース種別:
  • JaLC
  • Crossref
  • CiNii Articles
  • KAKEN
• 抄録ライセンスフラグ: 使用不可